Detailed Narrative
Q2 & H1 FY23 Financial Performance
Gujarat Themis Biosyn Limited reported robust financial results for Q2 FY23, with revenue growing 36.08% YoY to ₹47.69 crores and PAT increasing to ₹18.7 crores. EBITDA for the quarter stood at ₹24.4 crores, up 32.29% YoY, though the EBITDA margin saw a slight decline of 146 bps to 51.17%. For the first half of FY23, revenue rose 37.26% YoY to ₹92.64 crores, and PAT increased by 36.48% to ₹36.47 crores, with an EPS of ₹25.10.
Strategic Shift and Fermentation Expertise
The company successfully transitioned its business model in FY20 from contract manufacturing to an own manufacturing and sales model, which has significantly improved realizations and margins. GTBL leverages its strong R&D and technical know-how in fermentation chemistry, positioning itself as one of the few fermentation-based pharma intermediate manufacturers in India. Management highlighted the significant challenge of scaling up fermentation processes, an area where GTBL's long experience provides a competitive advantage.
Ambitious CAPEX Plans
GTBL announced a substantial CAPEX of ₹200 crores to be deployed over the next two to three years in a phased manner. This investment aims to bolster R&D capabilities, expand fermentation capacities, and facilitate forward integration into API manufacturing. Approximately ₹22 crores of this CAPEX has already been spent, primarily in CWIP, with plans to capitalize a new warehouse soon. The API plant alone is estimated to cost around ₹40 crores.
API Integration and Market Entry Strategy
A key component of the CAPEX is the development of a multi-purpose API block, which is targeted for commissioning by the end of Q2 FY2024. This facility will enable faster entry into the API market by initially producing APIs from sourced intermediates. The fermentation block is expected to follow, commissioning a year after the API facility. The company plans to target ROW, emerging markets, and also pursue US FDA approvals for its API products, indicating a global market strategy.
Capacity Utilization and Growth Outlook
Current manufacturing capacity utilization stands at a high 95%, which management acknowledged would limit volume growth in the immediate future until new capacities come online. While no immediate debottlenecking plans were confirmed, the company is exploring alternative strategies for volume growth beyond the next couple of quarters. The new API capacity is expected to significantly boost top-line and bottom-line growth once operational.
Funding and NSE Listing Plans
The CAPEX will be primarily funded through internal accruals, leveraging the company's strong cash flow and zero-debt position, with an option to raise debt if needed. Management also provided an update on its NSE listing plans, stating that the company expects to fulfill the net worth criteria (over ₹100 crores for 3 consecutive years) after the next financial year (FY24), after which it will 'most definitely' list on the NSE.
Competitive Landscape and Risk Mitigation
Management acknowledged the ongoing threat of predatory pricing from China but emphasized mitigation through product diversification and a focus on long-term contractual partnerships rather than spot businesses. While Rifaximin is considered a stable business, global factors like currency fluctuations can cause quarterly variations in supply. The company is strategically selecting new products to avoid crowded markets and ensure sustained profitability.